Haematopoietic stem cell transplantation (HCT) is a potentially curative treatment option for patients with malignant or non-malignant haematologic diseases. Acute graft-versus-host disease (GVHD) is a serious condition that arises as a complication in recipients of HCT from allogeneic donors. GVHD is a leading cause of mortality and morbidity in allogeneic HCT. Currently, few therapeutic options exist for the prevention of GVHD and all patients undergoing HCT typically receive immunosuppressive medications. These agents also increase the risk of infection and/or contribute to increases in relapse mortality due to enhanced immunosuppression. As such, there is a significant medical need to develop effective, less toxic preventative therapies for acute GVHD. We are currently investigating the potential of our plasma derived product Alpha-1 Antitrypsin (AAT) for the prevention of acute GVHD in patients receiving an allogenic HCT.
We are driven by our promise to bring lifesaving therapies to patients with rare disease and we are partnering with leading experts and worldwide regulatory authorities to deliver these novel immunomodulatory therapeutics to the field of transplantation.